Heart Disease, Stroke Risk Less with Glucose Control
Intensive glucose control lowers the risk of heart disease and stroke by about 50 percent in people with type 1 diabetes, researchers report in the New England Journal of Medicine.
Their findings are based on a follow-up study of patients who took part more than a decade ago in the Diabetes Control and Complications Trial (DCCT), a major clinical study funded by the National Institutes of Health (NIH).
“We see a greater reduction in cardiovascular events from intensive blood glucose control than from drugs that lower blood pressure and cholesterol,” says Dr. Saul Genuth, of Case Western Reserve University.
Dr. Genuth chairs the follow-up study of DCCT participants, called the Epidemiology of Diabetes Interventions and Complications (EDIC) study, which is examining the long-term effects of prior intensive blood glucose control versus conventional blood glucose control.
“The benefits of intensive control strongly reinforce the message that this therapy should begin as early as possible and be maintained as long as possible,” says Dr. Genuth.
“The risk of heart disease is about 10 times higher in people with type 1 diabetes than in people without diabetes,” adds Dr. David Nathan, of Massachusetts General Hospital and co-chair of the study.
“Maintaining tight control is difficult, but its advantages are huge," explains Dr. Nathan. "Intensive glucose control significantly reduces heart disease as well as damage to the eyes, nerves, and kidneys of people with type 1 diabetes.
"The longer we follow patients, the more we’re impressed by the lasting benefits of tight control,” he notes.
The DCCT results, announced in 1993, clearly showed that intensive glucose control prevents or delays the eye, nerve, and kidney complications of type 1 diabetes.
However, researchers had not followed participants long enough to know whether tight control also lowered the risk of heart attack and stroke.
The DCCT compared intensive management of blood glucose to conventional control in 1,441 people with type 1 diabetes.
Patients 13 to 39 years of age took part in the trial between 1983 and 1989. At the time, conventional treatment consisted of one or two insulin injections a day with daily urine or blood glucose testing.
Participants randomly assigned to intensive treatment were asked to keep glucose levels as close to normal as possible.
That meant trying to keep hemoglobin A1c (HbA1c) readings at 6 percent or less with at least three insulin injections a day or an insulin pump, guided by frequent self-monitoring of blood glucose. (HbA1c reflects average blood glucose over the past 2 to 3 months.)
Researchers announced the DCCT’s main results in 1993: intensive glucose control greatly lowers the eye, nerve, and kidney damage of type 1 diabetes.
At the end of the study, HbA1c readings averaged 7 percent in the intensively treated group and 9 percent in the conventionally treated patients, who were then encouraged to adopt intensive control and shown how to do it.
The DCCT findings prompted a major shift in the way physicians manage their patients with type 1 diabetes.
As researchers continued to follow participants, they saw that intensive treatment reduced the development of atherosclerosis, a finding published in 2003. They also observed a striking advantage of intensive control: its long-lasting effects.
The benefits of the first six years of intensive control persisted even though the blood glucose level of the intensively treated group had gradually risen to a HbA1c reading of about 8 percent, matching that of the conventionally treated group, which had declined.
In new results reported in the current study, tight glucose control lowered the risk of a cardiovascular disease (CVD) event by 42 percent and the risk of a serious event, including heart attack or stroke, by 58 percent.
Among the 1,375 volunteers continuing to participate in the study, the intensively treated patients had less than half the number of CVD events than the conventionally treated group (46 compared to 98 events).
Such events included heart attacks, stroke, angina, and coronary artery disease requiring angioplasty or coronary bypass surgery.
Thirty-one intensively treated patients (4 percent) and 52 conventionally treated patients (7 percent) had at least one CVD event during the average 17 years of follow-up from the start of the DCCT. The average age of participants is now 45 years, and 53 percent are male.
Always consult your physician for more information.
|
